# Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

> **NCT01215955** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1117 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin lispro
- **DRUG:** Glargine

## Key facts

- **NCT ID:** NCT01215955
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 1117 (ACTUAL)
- **Last updated:** 2014-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215955, "Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01215955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*